Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
1.559
-0.031 (-1.98%)
Nov 21, 2024, 1:29 PM EST - Market open
Atai Life Sciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 0.33 | 0.31 | 0.23 | 20.38 | - | - |
| Revenue Growth (YoY) | -0.90% | 34.76% | -98.86% | - | - | - |
| Gross Profit | 0.33 | 0.31 | 0.23 | 20.38 | - | - |
| Selling, General & Admin | 54.25 | 62.18 | 70.35 | 92.75 | 80.73 | 5.09 |
| Research & Development | 48.87 | 60.4 | 74.31 | 47.96 | 11.41 | 3.08 |
| Operating Expenses | 103.12 | 122.59 | 144.66 | 140.7 | 92.14 | 8.17 |
| Operating Income | -102.79 | -122.27 | -144.43 | -120.33 | -92.14 | -8.17 |
| Interest Expense | -2.66 | -2.66 | -0.92 | - | - | - |
| Interest & Investment Income | 1.85 | 1.85 | 0.55 | 0.21 | 0.07 | 0.02 |
| Earnings From Equity Investments | -2.39 | -3.59 | -16.01 | -58.56 | -76.51 | -6.91 |
| Currency Exchange Gain (Loss) | -0.89 | -0.89 | 6.9 | 8.48 | -0.19 | - |
| Other Non Operating Income (Expenses) | -108.55 | -0.81 | -0.21 | -0.34 | 0.01 | 0.36 |
| EBT Excluding Unusual Items | -215.43 | -128.37 | -154.12 | -170.53 | -168.77 | -14.7 |
| Merger & Restructuring Charges | -3.2 | -3.2 | - | - | - | - |
| Gain (Loss) on Sale of Investments | 86.29 | 86.29 | 0.3 | 4.58 | 19.86 | -0.63 |
| Gain (Loss) on Sale of Assets | 0.06 | 0.06 | 1.48 | - | - | - |
| Other Unusual Items | -0.1 | -0.1 | 1.5 | 3.2 | -17.39 | 0.62 |
| Pretax Income | -132.38 | -45.32 | -151.19 | -178.23 | -178.32 | -24.38 |
| Income Tax Expense | -2.18 | -1.43 | 6.23 | -3.99 | 0.31 | 0 |
| Earnings From Continuing Operations | -130.2 | -43.9 | -157.42 | -174.24 | -178.63 | -24.38 |
| Minority Interest in Earnings | 1.6 | 3.67 | 5.03 | 6.44 | 8.78 | 10.25 |
| Net Income | -128.6 | -40.22 | -152.39 | -167.81 | -169.84 | -14.14 |
| Net Income to Common | -128.6 | -40.22 | -152.39 | -167.81 | -169.84 | -14.14 |
| Shares Outstanding (Basic) | 162 | 159 | 156 | 138 | 93 | 9 |
| Shares Outstanding (Diluted) | 162 | 159 | 156 | 138 | 93 | 9 |
| Shares Change (YoY) | 3.48% | 2.00% | 12.62% | 48.64% | 973.40% | - |
| EPS (Basic) | -0.79 | -0.25 | -0.98 | -1.21 | -1.83 | -1.63 |
| EPS (Diluted) | -0.80 | -0.25 | -0.98 | -1.21 | -1.83 | -1.63 |
| Free Cash Flow | - | -84.38 | -105.24 | -64.42 | -20.83 | -7.87 |
| Free Cash Flow Per Share | - | -0.53 | -0.68 | -0.47 | -0.22 | -0.91 |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | - | - |
| Operating Margin | -31053.47% | -38939.81% | -61987.12% | -590.52% | - | - |
| Profit Margin | -38852.87% | -12810.19% | -65401.29% | -823.56% | - | - |
| Free Cash Flow Margin | - | -26871.66% | -45167.38% | -316.15% | - | - |
| EBITDA | -102.44 | -121.95 | -144.26 | -120.28 | -92.12 | -8.17 |
| D&A For EBITDA | 0.35 | 0.32 | 0.17 | 0.05 | 0.02 | 0.01 |
| EBIT | -102.79 | -122.27 | -144.43 | -120.33 | -92.14 | -8.17 |
Source: S&P Capital IQ. Standard template. Financial Sources.